This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified September 2016 by Laboratoire Ceraver-Osteal
Sponsor:
Information provided by (Responsible Party):
Laboratoire Ceraver-Osteal
ClinicalTrials.gov Identifier:
NCT01454271
First received: October 14, 2011
Last updated: September 13, 2016
Last verified: September 2016
  Purpose
The risk of infection after primary Total Hip Arthroplasties (THA)is generally estimated to be less than 1% but remains a severe and costly complication, source of morbidity and even mortality. The "biofilm" forms very early after the bacterial contamination of the prosthesis and poses a number of clinical challenges due to his resistance to immune defence mechanisms and antibiotics. Preventive strategies are needed. The poly sodium styrene sulfonate (pNaSS) is a bioactive polymer. In vitro and in vivo studies showed that poly sodium styrene sulfonate grafted on titane surfaces reduce significantly the bacterial adhesion. They also proved his biocompatibility and osseous-integration.

Condition Intervention Phase
Hip Arthroplasty Replacement Procedure: Total Hip Arthroplasty Replacement Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate

Further study details as provided by Laboratoire Ceraver-Osteal:

Primary Outcome Measures:
  • Femoral component osseous-integration [ Time Frame: 1 year after surgery ]
    Scoring system of Engh


Secondary Outcome Measures:
  • Infection rate [ Time Frame: 1 year after surgery ]

    Infection (yes/no) :

    Clinical, biological or radiological THA infection signs. In the case of infection suspicion, hip aspiration will be performed with joint fluid culture


  • Quality of Life [ Time Frame: One, three, six and twelve months after surgery ]
    SF-36 score


Estimated Enrollment: 50
Study Start Date: January 2017
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Total Hip Arthroplasty CERAFIT® grafted Procedure: Total Hip Arthroplasty Replacement
Total Hip Arthroplasty Replacement

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age less than 75 years old
  • Aetiologies for THA : primary osteoarthritis, inflammatory diseases,Osteonecrosis

Exclusion Criteria:

  • Previous infectious hip arthritis
  • Previous surgeries on the operated hip
  • Revision of THA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01454271

Contacts
Contact: Shahnaz Klouche, MD +33 (0) 6 28 35 04 78 klouche_shahnaz@yahoo.fr

Locations
France
Ambroise Paré Hospital. Orthopaedic surgery department Not yet recruiting
Boulogne-Billancourt, Ile de France, France, 92100
Principal Investigator: Philippe Hardy, Ph.D         
Sub-Investigator: Thomas Bauer, MD         
Sub-Investigator: Benoit Rousselin, MD         
Sponsors and Collaborators
Laboratoire Ceraver-Osteal
Investigators
Principal Investigator: Philippe Hardy, Ph.D. Ambroise Paré Hospital
  More Information

Responsible Party: Laboratoire Ceraver-Osteal
ClinicalTrials.gov Identifier: NCT01454271     History of Changes
Other Study ID Numbers: CERAVERBIO11
2011-A00597-34 ( Other Identifier: AFSSAPS )
Study First Received: October 14, 2011
Last Updated: September 13, 2016

Keywords provided by Laboratoire Ceraver-Osteal:
Total Hip arthroplasty
Hip Osteoarthritis
Infection after Total Hip Arthroplasty

ClinicalTrials.gov processed this record on August 23, 2017